OneSource Specialty Pharma Limited withdraws current merger plan with Steriscience entities
OneSource Specialty Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Board decided not to pursue composite scheme of arrangement and amalgamation now
- Decision made after meeting on May 13, 2026, despite earlier in-principle approval on February 26, 2026
- Will revisit the proposed transaction following successful delivery of FY28 guidance by respective companies
Why it's rated notable: The board's decision not to pursue the scheme is binding, but the filing states no value for the facilities, so the level stays at the default medium and is not sized against market value of ₹18,347 crore or annual revenue of ₹1,543 crore.
Original filing
Update On Composite Scheme Of Amalgamation
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from OneSource Specialty Pharma
- Capex / expansionNotableOneSource Specialty Pharma gets in-principle approval for Unit II expansion under KIP 2025–30
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.